ArticleMicroorganisms2026
Clinical Efficacy and Safety of Multiple High-Dose Antibiotic-Loaded Cement Spacers in the Two-Stage Revision of Gram-Positive Periprosthetic Joint Infection.
Article in Microorganisms, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Editorial for the Special Issue "Challenges of Biofilm-Associated Bone and Joint Infections".Microorganisms · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Periprosthetic joint infection (PJI) is a devastating complication after total joint arthroplasty, typically managed through a two-stage revision protocol involving antibiotic-loaded spacers. This study aimed to evaluate the clinical outcomes and safety of a new multiple high-dose antibiotic-loaded cement (MHDALC) spacer against alternative classical antibiotic combinations for Gram-positive PJI. In this retrospective observational study of 102 patients (30 MHDALC vs. 72 control), the MHDALC cohort received spacers prepared with commercial cement (1 g clindamycin and 1 g gentamicin per 40 g) supplemented with manual additions of 4 g vancomycin and 2 g ceftazidime per 40 g of cement, while the control group received the same commercial cement supplemented with 4 g of vancomycin alone. Treatment failure was significantly lower in the MHDALC group (6.6%) compared to the control group (20.8%;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.